Any patients with a diagnosis of spondyloarthritis according to his/her treating rheumatologist can be included

- Exclusion criteria

None

- mec approval received

no

- multicenter trial

yes

- randomised

no

- group

[default]

- Type

[default]

- Studytype

observational

- planned startdate

1-mei-2016

- planned closingdate

- Target number of participants

1000

- Interventions

None, daily care. Through MIJNREUMACENTRUM, a web-based patient medical file and at the same time a quality management system, patient outcome and pharmacovigilance data are prospectively gathered from spondyloarthritis patients in daily practice. These include patient reported outcomes, clinical examination and laboratory investigations.

- Primary outcome

Quality of life

- Secondary outcome

Disease activity state, work productivity

- Timepoints

Real-life, collection of data at each regular visit, scheduled according to treating rheumatologist

Spondyloarthritis (SpA) is a chronic and potentially disabling, inflammatory rheumatic disease, which needs long term monitoring and treatment. Despite its high prevalence and substantial socioeconomic impact, information on the quality of care delivered to these patients in daily practice in the Netherlands is scarce.
The aim of SpA-Net is to provide transparency on treatment and outcome of this disease in the Netherlands. Through MIJNREUMACENTRUM, a web-based patient medical file and at the same time a quality management system, patient outcome and pharmacovigilance data will be prospectively gathered from unselected SpA patients in daily practice.